`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`
`
`HOSPIRA, INC.,
`
`
`Plaintiff,
`
`v.
`
`AMNEAL PHARMACEUTICALS LLC,
`
`
`Defendant.
`
`C.A. No. 15-697-RGA
`
`AMNEAL'S SUPPLEMENTAL NOTICE OF DEPOSITION OF
`HOSPIRA, INC. PURSUANT TO FED. R. CIV. P. 30(b)(6)
`
`PLEASE TAKE NOTICE that, pursuant to Rule 30(b)(6) of the Federal Rules of Civil
`
`
`
`
`
`Procedure, Defendant Amneal Pharmaceuticals LLC (“Amneal”) by its attorneys, will take the
`
`deposition upon oral examination of Plaintiff Hospira, Inc. (“Hospira”), before a court reporter,
`
`notary public, or other person authorized by law to administer oaths and take testimony. The
`
`deposition will commence at 9:00 AM EST on December 16, 2016, at the offices of Sughrue
`
`Mion, PLLC, 2100 Pennsylvania Avenue, NW, Washington, DC 20037, or such other date, time,
`
`and location as may be mutually agreed to by counsel. The deposition will be recorded by
`
`stenographic means and will be videotaped. You are invited to attend and participate.
`
`
`
`PLEASE TAKE FURTHER NOTE that, pursuant to Rule 30(b)(6), Hospira is required to
`
`designate and produce one or more knowledgeable person to testify on its behalf with respect to
`
`the matters set forth in Schedule A, attached hereto. The person(s) so designated shall be
`
`required to testify as to those matters known or reasonably available to Hospira. Amneal
`
`requests that Hospira identify in writing at least ten (10) business days in advance of the
`
`
`
`Case 1:15-cv-00697-RGA Document 76 Filed 11/28/16 Page 2 of 4 PageID #: 936
`
`deposition, the name(s) and title(s) of the person(s) who will testify on its behalf and the subject
`
`matters on which each person will testify. You are invited to attend and cross-examine.
`
`
`
`
`
`/s/ Christine D. Haynes
`Kelly E. Farnan (#4395)
`Christine D. Haynes (#4697)
`Richards, Layton & Finger, P.A.
`920 North King Street
`Wilmington, DE 19801
`(302) 651-7700
`farnan@rlf.com
`haynes@rlf.com
`
`Attorneys for Defendant-Counterclaim Plaintiff
`Amneal Pharmaceuticals LLC
`
`
`2
`
`
`
`Of Counsel:
`Michael R. Dzwonczyk
`Azy S. Kokabi
`Grant S. Shackelford
`Sughrue Mion, PLLC
`2100 Pennsylvania Ave., NW
`Washington, DC 20037
`(202) 293-7060
`
`Dated: November 28, 2016
`
`
`
`
`
`
`
`
`
`Case 1:15-cv-00697-RGA Document 76 Filed 11/28/16 Page 3 of 4 PageID #: 937
`
`
`
`DEFINITIONS
`
`
`The definitions set forth in “AMNEAL'S NOTICE OF DEPOSITION OF HOSPIRA,
`
`INC. PURSUANT TO FED. R. CIV. P. 30(b)(6),” served August 31, 2016, are incorporated
`
`herein by reference into this document as if set forth in their entirety. Notwithstanding any
`
`applicable Definition, each word, term, or phrase used in these interrogatories is intended to have
`
`the broadest meaning permitted under the Federal Rules of Civil Procedure.
`
`
`
`
`
`3
`
`
`
`Case 1:15-cv-00697-RGA Document 76 Filed 11/28/16 Page 4 of 4 PageID #: 938
`
`
`
`SCHEDULE A
`SUPPLEMENTAL DEPOSITION TOPICS
`
`37.
`Hospira’s knowledge of products containing dexmedetomidine for veterinary use
`sold within the United States, including Dexdomitor®.
`
`
`
`
`4
`
`